Capital Impact Advisors LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,126 shares of the company's stock, valued at approximately $6,132,000. Medpace accounts for about 2.3% of Capital Impact Advisors LLC's investment portfolio, making the stock its 27th largest position. Capital Impact Advisors LLC owned about 0.07% of Medpace at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Sone Capital Management LLC bought a new stake in shares of Medpace in the 4th quarter worth approximately $1,318,000. GAMMA Investing LLC grew its position in shares of Medpace by 37.1% in the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after buying an additional 83 shares during the last quarter. Hsbc Holdings PLC grew its position in shares of Medpace by 157.5% in the 1st quarter. Hsbc Holdings PLC now owns 4,364 shares of the company's stock worth $1,296,000 after buying an additional 2,669 shares during the last quarter. Park Avenue Securities LLC grew its position in shares of Medpace by 1.8% in the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after buying an additional 48 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of Medpace by 70.7% in the 1st quarter. UMB Bank n.a. now owns 490 shares of the company's stock worth $149,000 after buying an additional 203 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Stock Down 1.3%
NASDAQ MEDP opened at $485.59 on Wednesday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The firm has a market capitalization of $13.64 billion, a PE ratio of 36.10, a P/E/G ratio of 3.10 and a beta of 1.44. The stock's 50 day moving average is $419.54 and its 200 day moving average is $346.21.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the previous year, the company posted $2.75 earnings per share. The firm's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.
Insiders Place Their Bets
In other Medpace news, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer directly owned 925,799 shares of the company's stock, valued at approximately $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the completion of the sale, the director directly owned 10,197 shares in the company, valued at $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 161,266 shares of company stock valued at $74,111,427. Company insiders own 20.30% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Mizuho lifted their price objective on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Rothschild Redb lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Truist Financial lifted their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $422.27.
View Our Latest Stock Analysis on MEDP
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
